SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1083 8791 "

Sökning: L773:1083 8791

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Arai, Sally, et al. (författare)
  • Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation : a report from the Center for International Blood and Marrow Transplant Research.
  • 2015
  • Ingår i: Biology of blood and marrow transplantation. - 1083-8791 .- 1523-6536. ; 21:2, s. 266-74
  • Tidskriftsartikel (refereegranskat)abstract
    • Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.
  •  
5.
  • Arnold, Staci D., et al. (författare)
  • The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia : A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis
  • 2020
  • Ingår i: Biology of blood and marrow transplantation. - : Elsevier BV. - 1083-8791 .- 1523-6536. ; 26:9, s. 1747-1756
  • Tidskriftsartikel (refereegranskat)abstract
    • Allogeneic hematopoietic stem cell transplantation (alloHCT) may be associated with significant morbidity and mortality, resulting in increased healthcare utilization (HCU). To date, no multicenter comparative cost analyses have specifically evaluated alloHCT in children with acute leukemia. In this retrospective cohort study, we examined the relationship between survival and HCU while investigating the hypothesis that matched sibling donor (MSD) alloHCT has significantly lower inpatient HCU with unrelated donor (URD) alloHCT, and that among URDs, umbilical cord blood (UCB) alloHCT will have higher initial utilization but lower long-term utilization. Clinical and transplantation outcomes data from the Center for International Blood and Marrow Transplant Research (CIBMTR) were merged with inpatient cost data from the Pediatric Health Information System (PHIS) database using a probabilistic merge methodology. The merged dataset comprised US patients age 1 to 21 years who underwent alloHCT for acute leukemia between 2004 and 2011 with comprehensive CIBMTR data at a PHIS hospital. AlloHCT was analyzed by donor type, with specific analysis of utilization and costs using PHIS claims data. The primary outcomes of overall survival (OS), leukemia-free survival (LFS), and inpatient costs were evaluated using Kaplan-Meier curves and Cox and Poisson models. A total of 632 patients were identified in both the CIBMTR and PHIS data. The 5-year LFS was 60% for MSD alloHCT, 47% for well-matched matched unrelated donor bone marrow (MUD) alloHCT, 48% for mismatched unrelated donor alloHCT, and 45% for UCB alloHCT (P = .09). Total adjusted costs were significantly lower for MSD alloHCT versus MUD alloHCT by day 100 (adjusted cost ratio [ACR], .73; 95% confidence interval [CI], .62 to .86; P < .001), and higher for UCB alloHCT versus MUD alloHCT (ACR, 1.27; 95% CI, 1.11 to 1.45; P < .001). By 2 years, total adjusted costs remained significantly lower for MSD alloHCT compared with MUD alloHCT (ACR, .67; 95% CI, .56 to .81; P < .001) and higher for UCB alloHCT compared with MUD alloHCT (ACR, 1.25; 95% CI, 1.02 to 1.52; P = .0280). Our data show that UCB and MUD alloHCT provide similar survival outcomes; however, MUD alloHCT has a significant advantage in cost by day 100 and 2 years. More research is needed to determine whether the cost difference among URD alloHCT approaches remains significant with a larger sample size and/or beyond 2 years post-alloHCT.
  •  
6.
  •  
7.
  • Ayas, Mouhab, et al. (författare)
  • Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure.
  • 2015
  • Ingår i: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. - 1523-6536 .- 1083-8791. ; 21:10
  • Tidskriftsartikel (refereegranskat)abstract
    • A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individuals who develop graft failure after their first HCT. Data on outcomes after second HCT in patients with Fanconi anemia (FA) are scarce. Here we report outcomes after second allogeneic HCT for FA (n = 81). The indication for second HCT was graft failure after the first HCT. Transplantations were performed between 1990 and 2012. The timing of the second HCT predicted subsequent graft failure and survival. Graft failure was high when the second HCT was performed less than 3 months from the first. The 3-month probability of graft failure was 69% when the interval between the first HCT and second HCT was less than 3 months, compared with 23% when the interval was longer (P < .001). Consequently, the 1-year survival rate was substantially lower when the interval between the first and second HCTs was less than 3 months compared with longer (23% vs 58%; P = .001). The corresponding 5-year probability of survival was 16% and 45%, respectively (P = .006). Taken together, these data suggest that fewer than one-half of patients with FA undergoing a second HCT for graft failure are long-term survivors. There is an urgent need to develop strategies to reduce the rate of graft failure after first HCT.
  •  
8.
  •  
9.
  •  
10.
  • Bejanyan, Nelli, et al. (författare)
  • Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation
  • 2018
  • Ingår i: Biology of blood and marrow transplantation. - 1083-8791 .- 1523-6536. ; 24:5, s. 945-955
  • Tidskriftsartikel (refereegranskat)abstract
    • Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving ≥2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk, 1.20, 95% confidence interval, .86 to 1.67; P = .28 for no consolidation; RR, 1.18, 95% confidence interval, .79 to 1.76; P = .41 for 1 cycle versus ≥2 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (82)
konferensbidrag (82)
forskningsöversikt (1)
Typ av innehåll
övrigt vetenskapligt (88)
refereegranskat (77)
Författare/redaktör
Ringden, O (65)
Remberger, M. (44)
Mattsson, J. (39)
Olsson, RF (28)
Gale, RP (26)
Savani, BN (24)
visa fler...
Lazarus, HM (23)
Olsson, Richard (21)
Kamble, RT (21)
Lazarus, Hillard M (21)
Savani, Bipin N (21)
Ganguly, S (19)
Gale, Robert Peter (19)
Uhlin, M. (18)
Olsson, Richard F (18)
Kamble, Rammurti T. (18)
Nishihori, T (17)
Seo, S (17)
Saber, Wael (17)
Hematti, P (17)
Marks, DI (16)
Aljurf, M (16)
Saber, W (16)
Seo, Sachiko (15)
Chhabra, S (15)
Marks, David I. (15)
Olsson, R (14)
Abdel-Azim, Hisham (14)
Aljurf, Mahmoud (14)
Abdel-Azim, H (14)
Wirk, Baldeep (14)
Akpek, G (13)
Sundberg, B. (12)
Le Blanc, K (12)
Hematti, Peiman (12)
Freytes, CO (12)
Gergis, U (11)
Gustafsson, B. (11)
Ljungman, P (11)
Cerny, J (11)
Gergis, Usama (11)
Pulsipher, Michael A ... (11)
Diaz, MA (10)
Cerny, Jan (10)
Hamadani, Mehdi (10)
Hamadani, M (10)
Cahn, JY (10)
Inamoto, Y (10)
Freytes, Cesar O. (10)
Pulsipher, MA (10)
visa färre...
Lärosäte
Karolinska Institutet (144)
Uppsala universitet (49)
Göteborgs universitet (9)
Lunds universitet (9)
Umeå universitet (2)
Kungliga Tekniska Högskolan (2)
visa fler...
Örebro universitet (1)
Linköpings universitet (1)
Malmö universitet (1)
Linnéuniversitetet (1)
visa färre...
Språk
Engelska (165)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (64)
Naturvetenskap (5)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy